In vitro and in vivo evaluation of SN-38 nanocrystals with different particle sizes

被引:19
作者
Chen, Min [1 ,2 ]
Li, Wanqing [3 ]
Zhang, Xun [1 ]
Dong, Ye [1 ]
Hua, Yabing [1 ]
Zhang, Hui [1 ]
Gao, Jing [1 ]
Zhao, Liang [2 ]
Li, Ying [1 ]
Zheng, Aiping [1 ]
机构
[1] Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, 27 Taiping Rd, Beijing 100850, Peoples R China
[2] Jinzhou Med Univ, Sch Pharm, Jinzhou, Peoples R China
[3] Beijing Univ Chinese Med, Sch Preclin Med, Beijing, Peoples R China
来源
INTERNATIONAL JOURNAL OF NANOMEDICINE | 2017年 / 12卷
基金
北京市自然科学基金; 中国国家自然科学基金;
关键词
SN-38; nanocrystals; antitumor efficacy; cellular uptake; pharmacokinetics; tissue distribution; POORLY SOLUBLE DRUGS; ANTITUMOR-ACTIVITY; NANOSUSPENSION TECHNOLOGY; LIPID NANOPARTICLES; ACTIVE METABOLITE; DELIVERY; FORMULATION; SN38; CAMPTOTHECIN; TUMOR;
D O I
10.2147/IJN.S133816
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
7-Ethyl-10-hydroxycamptothecin (SN-38) is a potent broad-spectrum antitumor drug derived from irinotecan hydrochloride (CPT-11). Due to its poor solubility and instability of the active lactone ring, its clinical use is significantly limited. As one of the most promising formulations for poorly water-soluble drugs, nanocrystals have attracted increasing attention. In order to solve these problems and evaluate the antitumor effect of SN-38 in vitro and in vivo, two nanocrystals with markedly different particle sizes were prepared. Dynamic light scattering and transmission electron microscopy were used to investigate the two nanocrystals. The particle sizes of SN-38 nanocrystals A (SN-38/NCs-A) and SN-38 nanocrystals B (SN-38/NCs-B) were 229.5 +/- 1.99 and 799.2 +/- 14.44 nm, respectively. X-ray powder diffraction analysis showed that the crystalline state of SN-38 did not change in the size reduction process. An accelerated dissolution velocity of SN-38 was achieved by nanocrystals, and release rate of SN-38/NCs-A was significantly faster than that of SN-38/NCs-B. Cellular uptake, cellular cytotoxicity, pharmacokinetics, animal antitumor efficacy, and tissue distribution were subsequently examined. As a result, enhanced intracellular accumulation in HT1080 cells and cytotoxicity on different tumor cells were observed for SN-38/NCs-A compared to that for SN-38/NCs-B and solution. Besides, compared to the SN-38 solution, SN-38/NCs-A had a higher bioavailability after intravenous injection; while the bioavailability of SN-38/NCs-B was even lower than that of the SN-38 solution. SN-38/NCs-A exhibited a significant inhibition of tumor growth compared to SN-38 solution and SN-38/NCs-B in vivo. The antitumor effect of SN-38/NCs-B was stronger than SN-38 solution. The tissue distribution study in tumor-bearing mice showed that nanocrystals could markedly improve the drug accumulation in tumor tissue by the enhanced permeability and retention effect compared to SN-38 solution, and the amount of SN-38 in tumors of SN-38/NCs-A group was much more than that of SN-38/NCs-B group. In conclusion, nanocrystals dramatically enhanced the anticancer efficacy of SN-38 in vitro and in vivo, and the particle size had a significant influence on the dissolution behavior, pharmacokinetic properties, and tumor inhibition of nanocrystals.
引用
收藏
页码:5487 / 5500
页数:14
相关论文
共 48 条
  • [1] Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors
    Ali, Hany S. M.
    York, Peter
    Blagden, Nicholas
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 375 (1-2) : 107 - 113
  • [2] Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38
    Bala, Vaskor
    Rao, Shasha
    Boyd, Ben J.
    Prestidge, Clive A.
    [J]. JOURNAL OF CONTROLLED RELEASE, 2013, 172 (01) : 48 - 61
  • [3] Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice
    Chu, Celine
    Abbara, Chadi
    Tandia, Mahamadou
    Polrot, Melanie
    Gonin, Patrick
    Farinotti, Robert
    Bonhomme-Faivre, Laurence
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2014, 28 (06) : 652 - 660
  • [4] Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach
    des Rieux, Anne
    Fievez, Virginie
    Garinot, Marie
    Schneider, Yves-Jacques
    Preat, Veronique
    [J]. JOURNAL OF CONTROLLED RELEASE, 2006, 116 (01) : 1 - 27
  • [5] Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms
    Dressman, JB
    Amidon, GL
    Reppas, C
    Shah, VP
    [J]. PHARMACEUTICAL RESEARCH, 1998, 15 (01) : 11 - 22
  • [6] Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery
    Ganta, Srinivas
    Paxton, James W.
    Baguley, Bruce C.
    Garg, Sanjay
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 367 (1-2) : 179 - 186
  • [7] Studies on the preparation, characterization and pharmacokinetics of Amoitone B nanocrystals
    Hao, Leilei
    Wang, Xiaoyong
    Zhang, Dianrui
    Xu, Qingyan
    Song, Siyang
    Wang, Feihu
    Li, Caiyun
    Guo, Hejian
    Liu, Yue
    Zheng, Dandan
    Zhang, Qiang
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2012, 433 (1-2) : 157 - 164
  • [8] Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
    Hobbs, SK
    Monsky, WL
    Yuan, F
    Roberts, WG
    Griffith, L
    Torchilin, VP
    Jain, RK
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (08) : 4607 - 4612
  • [9] Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide
    Jacobs, C
    Kayser, O
    Müller, RH
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 196 (02) : 161 - 164
  • [10] KAWATO Y, 1991, CANCER RES, V51, P4187